Terbinafine topical

Drug Profile

Terbinafine topical

Alternative Names: MOB-015; MOB015B

Latest Information Update: 14 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Moberg Derma
  • Developer Moberg Pharma
  • Class Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Onychomycosis

Highest Development Phases

  • Phase III Onychomycosis

Most Recent Events

  • 01 Aug 2017 Moberg Pharma AB plans a phase I trial for Onychomycosis (In adolescents, In adults, In the elderly) (Topical) (NCT03244280)
  • 01 Sep 2016 Phase-III clinical trials in Onychomycosis (In adolescents, In adults, In the elderly) in USA and Canada (Topical) (NCT02859519)
  • 01 Sep 2016 Phase-III clinical trials in Onychomycosis (In adults, In the elderly) in Germany (Topical) (NCT02866032)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top